Learn more about The Hugh and Herbert Hoffman ALS Impact Fund Your Actions Make a Difference Thanks to the generous support of our donors, we are leading the fight against ALS by investing millions in groundbreaking research, ensuring access to quality care and disease education, advocating for policy change, and raising awareness through community events
10.7759/cureus.50725 Cureus
Cagrilintides monotherapy evidence reaches only Phase 2: a dose-finding trial established a doseresponse on bodyweight versus placebo and versus an active comparator
Kurinna S, Konopleva M, Palla SL, Chen W, Kornblau S, Contractor R, Deng X, May WS, Andreeff M , Ruvolo PP
So, in March 2023, Madison started GLP-1 medication through Claya, a weight loss and wellness company